Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original article

Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis

Li-Chin Lu a,1, Chien-Ming Chao b,1, Shen-Peng Chang c, Shao-Huan Lan d, Chih-Cheng Lai e,d,⁎

a School of Management, Putian University, Putian 351100, China
b Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan
c Yijia Pharmacy, Tainan 70846, Taiwan
d School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian 351100, China
e Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan

A R T I C L E  I N F O

Article history:
Received 13 July 2022
Received in revised form 7 September 2022
Accepted 9 October 2022

Keywords:
COVID-19
Emergency department
Fluvoxamine
Hospitalization
SARS-CoV-2

A B S T R A C T

Objectives: This meta-analysis investigated the use of fluvoxamine for the treatment of nonhospitalized patients with COVID-19.

Methods: PubMed, Web of Science, Ovid medline, Embase, Scopus, Cochrane Library databases, and ClinicalTrials.gov were searched for studies published before June 25, 2022. Only clinical studies that compared the efficacy and safety of fluvoxamine with other alternatives or placebos in the treatment of nonhospitalized patients with COVID-19 were included.

Results: Four studies with 1814 patients, of whom 912 received fluvoxamine, were included in this study. Compared with the control group receiving placebo or no therapy, the study group receiving fluvoxamine demonstrated a lower risk of hospitalization and emergency department (ED) visits (odds ratio [OR], 0.59; 95% CI, 0.44–0.79; I² = 26%). In addition, the rate of hospitalization remained significantly lower in patients who received fluvoxamine than in the control group (OR, 0.69; 95% CI, 0.51–0.94; I² = 36%). Although the study group demonstrated a lower risk of requirement of mechanical ventilation and intensive care unit admission, and mortality than the control group, these differences were nonsignificant. Finally, fluvoxamine use was associated with a similar risk of adverse events as that observed in the control group.

Conclusion: Fluvoxamine can be safely used in nonhospitalized patients with COVID-19 and can reduce the hospitalization rate or ED visits in these patients.

© 2022 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Since the end of 2019, when the first outbreak of COVID-19 caused by SARS-CoV-2 occurred in Wuhan, China, more than 545 million COVID-19 cases have been confirmed, with more than 6 million deaths as of July 1, 2021 [1,2]. The clinical spectrum of COVID-19 ranges from asymptomatic infection to acute respiratory distress syndrome or critical illness [3,4]. Although > 80% of patients with COVID-19 present with asymptomatic or mild disease with favorable clinical outcome, some may progress to severe illness and require emergency department (ED) visits or hospitalization, particularly those with older age, obesity, cardiovascular diseases, chronic lung disease, diabetes, and immunocompromised status [3]. Therefore, prevention of disease progression, which contributes to ED visits or hospitalization, in patients with mild or moderate COVID-19 is a critical topic.

However, knowledge on effective agents for the treatment of nonhospitalized patients with mild to moderate COVID-19 is limited. Neutralizing monoclonal antibodies, which can interact with the surface spike glycoprotein of SARS-CoV-2, thereby preventing viral attachment and infectivity, show promise in lowering the incidence of COVID-19-related hospitalization and mortality and accelerating viral load decline [5–8]. However, neutralizing monoclonal antibodies are costly and some of them were not effective in the management of omicron variant. Therefore, drug repurposing is necessary to discover readily available, safe, and inexpensive drugs that can help manage mild COVID-19.

https://doi.org/10.1016/j.jiph.2022.10.010

1876-0341/© 2022 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A recent observational, multicenter, retrospective cohort study that enrolled 7230 adults hospitalized for COVID-19, in which 345 patients (4.8%) received an antidepressant within 48 h of hospital admission, reported that antidepressant use may be associated with lower risk of mortality or intubation in patients hospitalized for COVID-19 [9]. Fluvoxamine is a selective serotonin reuptake inhibitor and a strong agonist for the σ-1 receptor, which helps control inflammation [10]. In addition to its anti-inflammatory effect, fluvoxamine may exhibit an antiviral effect and ameliorate cytokine response through various mechanisms, including by enhancing mast cell degranulation, interfering in endolysosomal viral trafficking, and increasing melatonin level [10]. Furthermore, fluvoxamine can inhibit acid sphingomyelinase activity, the formation of ceramide-enriched membrane domain, and attenuates SARS-CoV-2 cell entry [11,12]. Moreover, fluvoxamine can act as a potent sigma-1 receptor agonist that may decrease SARS-CoV-2 replication and subsequent endoplasmic reticulum stress and inflammation [12,13]. Thus, fluvoxamine was repurposed as a potential agent against SARS-CoV-2 infection [14]. Moreover, several clinical studies, including randomized controlled trials (RCTs), have demonstrated the benefit of fluvoxamine in the treatment of nonhospitalized patients with COVID-19 [15–17]. Therefore, we conducted this systematic review and meta-analysis of clinical studies to provide robust and up-to-date evidence of the clinical efficacy and safety of fluvoxamine for patients with COVID-19 treated as outpatients.

Methods

Search strategy

We searched the PubMed, Web of Science, Ovid medline, Embase, Scopus, Cochrane Library databases and ClinicalTrials.gov for relevant articles from their inception to June 25, 2022. The following search terms were used: “COVID-19,” “coronavirus infections,” “coronavirus,” “corona infection,” “SARS-CoV-2,” “fluvoxamine,” and “fluvox.” This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines [18]. The protocol of the systematic review and meta-analysis was registered at PROSPERO (CRD42021289764).

Inclusion and exclusion criteria

Only clinical studies that assessed the clinical efficacy of fluvoxamine in the treatment of nonhospitalized patients with COVID-19 were included. We also manually searched for additional eligible articles from the reference lists of relevant articles. Studies were included if they met the following criteria: (1) included nonhospitalized patients with confirmed COVID-19; (2) used fluvoxamine as intervention; (3) used placebo or alternative agents as comparator; (4) was an RCT or observational cohort study; and (5) reported of clinical efficacy as a study outcome.

The exclusion criteria were as following: (1) nonhuman studies, reviews, or meta-analyses; (2) studies without adequate data for outcome analysis; and (3) poster or conference abstracts.

Data extraction

Two authors (SHL and CMC) independently screened and identified articles to avoid bias. A third author (LCL) was consulted in cases of disagreement over the same publication and made the final decision. The following data were extracted separately by 2 authors (CCL and SPC) from each included study: year of publication, study design, fluvoxamine regimen, clinical outcomes, and risk of adverse events (AEs). If the extracted data were inconsistent, a third author (LCL) was consulted. The primary outcome was risk of hospitalization or ED visits. Secondary outcomes were requirement of mechanical ventilation (MV) and intensive care unit (ICU) admission, risk of mortality, and risk of AEs.

Statistical analysis

We used the RoB 2.0 [19] to assess the quality of included studies and risk of bias and Review Manager using random (version 5.3; Nordic Cochrane Centre, Copenhagen, Denmark) for statistical analysis.
Non-hospitalized adults with COVID-19 study subjects used fluvoxamine 100 mg twice daily for 10 days in a placebo-controlled, randomized, 756 study. California, US Regimen of fluvoxamine: Prospective open-label cohort study Unvaccinated Non-hospitalized adults with COVID-19 and a known risk factor for progression to severe disease

Table 1

Study characteristics

Study site

Lenze et al., 2020 St Louis metropolitan area, US Randomized clinical trial

Seftel et al., 2021 11 clinical sites in Brazil Adaptive platform trial

Reis et al., 2021 Seoul, Korea Placebo-controlled randomized trial

Seo et al., 2022 Seoul, Korea Placebo-controlled randomized trial

Study design

Double-blind, placebo-controlled, multicenter clinical trial in Brazil Non-hospitalized adults with COVID-19 and a known risk factor for progression to severe disease

Table 2

Vaccine status

Control group

No of study patients

Characteristics of included studies.

Study design

double-blind, placebo-controlled, multicenter clinical trial in Brazil Non-hospitalized adults with COVID-19 and a known risk factor for progression to severe disease

Table 2

Vaccine status

Control group

No of study patients

Survey of included studies.

Study site

lenze et al., 2020 St Louis metropolitan area, US Randomized clinical trial

Seftel et al., 2021 11 clinical sites in Brazil Adaptive platform trial

Reis et al., 2021 Seoul, Korea Placebo-controlled randomized trial

Seo et al., 2022 Seoul, Korea Placebo-controlled randomized trial

Primary outcome

The rate of hospitalization or ED visits in patients who received fluvoxamine was only 8.8 % (82/912), which was much lower than that in controls who received placebo or no therapy (14.5 %, 131/912). A significant difference in the rate of hospitalization or ED visits was observed between patients who received fluvoxamine and those who received placebo (OR, 0.59; 95 % CI, 0.44–0.79; \( I^2 = 26 \% \), Fig. 3). This difference remained significant in the leave-one-out sensitivity test, in which individual studies were randomly excluded. When the results of the three RCTs were pooled [15,17,20], fluvoxamine was associated with a lower risk of hospitalization or ED visits than placebo (OR, 0.632; 95 % CI, 0.47–0.85; \( I^2 = 0 \% \)). The rate of hospitalization remained significantly lower in patients who received fluvoxamine than in the control group in the pooled analysis of all included studies (OR, 0.69; 95 % CI, 0.51–0.94; \( I^2 = 36 \% \), Fig. 4).

Secondary outcomes

Regarding the mortality risk, 17 of 912 patients who received fluvoxamine died compared with 26 of 902 patients in the control group. The mortality rate was lower in the study group than in the control group, but the difference did not reach statistical significance (OR, 0.66; 95 % CI, 0.36–1.21; \( I^2 = 0 \% \)). Although the rate of MV or ICU
admission requirement was lower in the study group than in the control group, the difference was nonsignificant (MV use: 2.9 % vs. 4.2 %; OR, 0.70; 95 % CI, 0.43–1.16; P = 0.20). The results remained unchanged in the pooled analysis of the three RCTs [15,17,20].

The pooled analysis of the 3 RCTs [15,17,20] revealed that the risks of any AE and serious AE were similar between fluvoxamine and placebo (any AE: OR, 1.33; 95 % CI, 0.51–3.44; I² = 70 %; serious AE: OR, 0.47; 95 % CI, 0.09–2.54; I² = 63 %, Fig. 5). Additionally, the risk of discontinuation of the study drug because of AE in patients receiving fluvoxamine was comparable with that in patients receiving placebo (OR, 2.60; 95 % CI, 0.45–15.11; I² = 65 %) in the pooled analysis of two RCTs [17,20] with available data. In Seftel et al.’s study [16], no patient receiving fluvoxamine experienced serious AE or discontinued the study drug because of AE.

Discussion

In this meta-analysis, four studies [15–17,20] including three RCTs were reviewed to compare the efficacy and safety of fluvoxamine in the treatment of nonhospitalized patients with COVID-19. First, we found that fluvoxamine can significantly reduce the risk of hospitalization or ED visits, which remained consistent in the leave-one-out sensitivity test and subgroup analysis of the three RCTs. In addition, fluvoxamine was associated with a significantly lower rate of COVID-19 related hospitalization than the comparators. Second, although we observed that those who used fluvoxamine had a requirement of MV and ICU admission, and mortality than those who received placebo or no therapy, these differences were nonsignificant; this may be attributable to the low number of events. Finally, we found no evidence that fluvoxamine was associated with a higher risk of AE compared with placebo or no therapy. Overall, based on the aforementioned findings, fluvoxamine appears to be an effective and safe agent to prevent hospitalization or ED visits in nonhospitalized patients with COVID-19. These findings were consistent with previous meta-analyses [21,22] of only RCTs. However, the present study including both RCTs and observational studies. In addition, one of included RCTs was reported in 2022 and conducted in Asia [20]. Therefore, our findings are more updated and generalizable than previous meta-analyses [21,22].

In addition to nonhospitalized patients, one recent open label, prospective cohort trial with matched controls reported that adding fluvoxamine to the standard therapy for patients with COVID-19 in the ICU can have a positive impact on patient survival (hazard ratio, 0.58; 95 % CI, 0.36–0.94, P = .027) [23]. According to our findings on the efficacy and safety of fluvoxamine for nonhospitalized patients with COVID-19, fluvoxamine may be of use during the COVID-19 pandemic. Crucially, this treatment is readily available and inexpensive, in contrast to the newly developed neutralizing monoclonal antibodies [24] and promising antiviral agent molnupiravir [25].

This study has several limitations. First, the analyses of the risk of AE were based on analysis of data that exhibited high heterogeneity (I² > 50 %). The heterogeneity could be a result of the small case and

---

**Table 2**

Demographic characteristics of patients.

| Race/Ethnicity            | Lenze et al., 2020 | Reis et al., 2021 | Seftel et al., 2021 | Seo et al., 2022 |
|---------------------------|-------------------|-------------------|-------------------|-------------------|
| Control group             | Study group       | Control group     | Study group       | Control group     |
| Age ≥ 50 years            | 46 (35–58)        | 40 (35–54)        | 19 (35)           | 35 (34–46)        |
| Body-mass index ≥ 30 kg/m²| 43 (54)           | 42 (58)           | 37 (51)           | 37 (45)           |
| Male                      | 24 (30)           | 19 (26)           | 32 (45)           | 30 (40)           |
| Age ≥ 50 years            | NA                | NA                | 32 (44)           | NA                |
| Body-mass index ≥ 30 kg/m²| NA                | NA                | 37 (50)           | NA                |
| Male                      | 24 (30)           | 19 (26)           | 32 (45)           | 30 (40)           |
| Race/Ethnicity            | NA                | NA                | 32 (44)           | NA                |
| Control group             | Study group       | Control group     | Study group       | Control group     |
| Age ≥ 50 years            | 46 (35–58)        | 40 (35–54)        | 19 (35)           | 35 (34–46)        |
| Body-mass index ≥ 30 kg/m²| 43 (54)           | 42 (58)           | 37 (51)           | 37 (45)           |
| Male                      | 24 (30)           | 19 (26)           | 32 (45)           | 30 (40)           |
| Age ≥ 50 years            | NA                | NA                | 32 (44)           | NA                |
| Body-mass index ≥ 30 kg/m²| NA                | NA                | 37 (50)           | NA                |
| Male                      | 24 (30)           | 19 (26)           | 32 (45)           | 30 (40)           |
| Race/Ethnicity            | NA                | NA                | 32 (44)           | NA                |

NA, not applicable.
Second, the number of studies included and total number of patients in three of four included studies [15, 16, 20] were limited. By contrast, the TOGETHER randomized, platform clinical trial [17] was much larger than all the other three studies combined, and therefore, the results of this trial likely strongly affected the outcome of the present meta-analysis. However, we used the leave-one-out sensitivity test to assess the effect of individual studies and the results remained consistent. Finally, three trials excluded fully vaccinated individuals, therefore any estimates of absolute effect size would likely be an overestimate in vaccinated patients. Further study is warranted to assess the effect of fluvoxamine on the outcome of vaccinated patients with COVID-19.

In conclusion, fluvoxamine use can help reduce the risk of hospitalization or ED visits for nonhospitalized COVID-19 patients. Furthermore, this drug was found to be safe for use in COVID-19 treatment. However, the present evidence is insufficient to support recommending fluvoxamine in the treatment of nonhospitalized patients with COVID-19.

Funding

This study received no funding.

CRediT authorship contribution statement

Conception: LCL, CMC, CCL; Study design: LCL, SPC, SHL, CCL; Analysis and interpretation: CMC, SPC, and CCL; Drafted or written: LCL, CMC, CCL; Substantial revision or critical review: CCL; All authors have agreed on the journal to which the article will be submitted and have reviewed and agreed on all versions of the article before submission, during revision, the final version accepted for publication, and any significant changes introduced at the proofing stage. In addition, all authors agree to take responsibility and be accountable for the contents of the article and to share responsibility to resolve any questions raised on the accuracy or integrity of the published work.
Data Availability

Data sharing not applicable – no new data generated.

Competing interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.

Acknowledgments

None.

Ethical approval

Not required.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.jiph.2022.10.010.

References

[1] World Health Organization. https://covid19.who.int/ Accessed on July 1, 2021.
[2] Lai CC, Shih TP, Ko WC, Tang HJ, Hsieh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):105924.
[3] Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med 2020;383(18):1757–66.
[4] Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect 2020;53(3):404–12.
[5] Doughan M, Nirula A, Azzad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med 2021;385(15):1382–92.
[6] Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021;384(3):229–37.
[7] Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 2021;325(7):632–44.
[8] Gupta A, Gonzalez-Rojas Y, Suarez E, Casal MC, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrivid. N Engl J Med 2021.
[9] Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry 2021;26(9):5199–212.
[10] Sukhatme VP, Reiersen AM, Vaytendt SJ. Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharm 2021;12:632688.
[11] Kornhuber J, Hoertel N, Gubins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry 2022;27(1):307–14.
[12] Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry 2022;27(4):1898–907.
[13] Mueller JR, Riederer P, Müller WE. Neuropsychiatric drugs against COVID-19: What is the clinical evidence? Pharmacopsychiatry 2022;55(1):7–15.
[14] Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci 2022;272(1):161–3.
[15] Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020;324(22):2292–300.
[16] Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis 2021;8(2):ofab050.
[17] Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres A C, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022;10(1):e42–51.
[18] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
[19] Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boultron I, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
[20] Seo H, Kim H, Bae S, Park S, Chung H, Sung HS, et al. Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: a preliminary result of randomized controlled trial. Infect Chemother 2022;54(1):102–13.
[21] Guo CM, Hariari O, Chernecki C, Thorlund K, Forrest JL. Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials. Am J Trop Med Hyg 2022;106(5):1315–20.
[22] Lee TC, Vogod S, Bortolussi-Courval É, Hanula R, Boulware DR, Lenze EJ, et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. JAMA Netw Open 2022;5(4):e226269.
[23] Calusic M, Marcere R, Luksa L, Jurkovis I, Kovac N, Mihaljevic S, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmac 2022;88(5):2063–73.
[24] Deeks ED. Casirivimab/Imdevimab: first approval. Drugs 2021;81(17):2047–55.
[25] Mahase E. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ 2021;375:n2422.

L.-C. Lu, C.-M. Chao, S.-P. Chang et al. Journal of Infection and Public Health 15 (2022) 1259–1264